alirocumab vs bempedoic acid/ezetimibe
Side-by-side comparison of alirocumab and bempedoic acid/ezetimibe Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Praluent
Nexlizet
Praluent is a medicine that can lower cholesterol. It can also lower the risk of heart problems like heart attack or stroke in some adults.
Nexlizet is a combination medicine that helps lower cholesterol. It is used with diet and exercise to lower LDL-C (bad cholesterol) in adults.
Praluent is used to lower LDL cholesterol (bad cholesterol). It is used along with diet and exercise in adults with high cholesterol. It is also used in adults and children 8 years and older who have a genetic condition that causes high cholesterol.
Nexlizet is used to lower LDL-C (bad cholesterol) in adults who have high cholesterol. This includes people with a genetic condition called heterozygous familial hypercholesterolemia (HeFH). One of the medicines in Nexlizet can also lower the risk of heart problems like heart attack and stroke in adults who are at high risk and cannot take statins.
Praluent is a PCSK9 inhibitor. It works by blocking a protein in your body called PCSK9. Blocking this protein helps your body remove LDL cholesterol from your blood.
Nexlizet contains two medicines that work in different ways to lower cholesterol. Bempedoic acid blocks an enzyme in your liver that makes cholesterol. Ezetimibe stops your body from absorbing cholesterol from food.
- • Injection site reactions (redness, itching, swelling, pain)
- • Flu
- • Muscle pain
- • Diarrhea
- • Upper respiratory tract infection (like a cold)
- • Muscle spasms
- • High uric acid levels in the blood
- • Back pain
- • Stomach pain or discomfort
- Muscle pain 1,655
- Missed dose 1,364
- Pain at injection site 1,278
- Muscle spasms 1,162
- Joint pain 1,053
- Muscle pain 53
- Joint pain 51
- Pain in your arms or legs 40
- Muscle spasms 32
- Tiredness 30
Serious allergic reactions have happened with Praluent, sometimes requiring hospitalization. If you have signs of a serious allergic reaction, stop using Praluent and get medical help right away.
This medicine can raise uric acid levels in your blood, which can cause gout. Tell your doctor if you have symptoms of high uric acid, like joint pain or swelling. Nexlizet can also increase your risk of tendon rupture. Stop taking Nexlizet and call your doctor right away if you have tendon pain, swelling, or difficulty moving.
There is not enough information about Praluent use during pregnancy to know if it is safe. If you are pregnant or plan to become pregnant, talk to your doctor before using Praluent.
This medicine may harm your unborn baby. Do not take Nexlizet if you are pregnant or planning to become pregnant. Talk to your doctor about other ways to lower your cholesterol during pregnancy.
Also Compare — Nearby Drugs
Compare alirocumab with
How to Read This alirocumab vs bempedoic acid/ezetimibe Comparison
alirocumab is classified in the PCSK9 Inhibitor drug class, while bempedoic acid/ezetimibe sits within the ACL Inhibitor / Cholesterol Absorption Inhibitor class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, alirocumab has 6,512 submissions while bempedoic acid/ezetimibe has 206. Those figures reflect cumulative reporting volume — not per-patient risk — so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between alirocumab and bempedoic acid/ezetimibe — always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.